Brief: Galecto Announces Outcome Of Data Safety Monitoring Board Interim Review Of Phase 2B Galactic-1 Study Of Gb0139

Damora Therapeutics

15/03/2021 11:41

March 15 (Reuters) - Galecto Inc  GLTO.O :
    * GALECTO ANNOUNCES OUTCOME OF DATA SAFETY MONITORING BOARD
INTERIM REVIEW OF PHASE 2B GALACTIC-1 STUDY OF GB0139 FOR
IDIOPATHIC PULMONARY FIBROSIS: DSMB RECOMMENDS STUDY TO CONTINUE
WITH MODIFICATIONS
    * GALECTO - DSMB RECOMMENDED CO DISCONTINUE DOSING &
ENROLLING
PATIENTS IN 10 MG ARM WITH PATIENTS IN 3 MG ARM RECEIVING
COMBINATION TREATMENT WITH TREATMENTS OF IPF
    * GALECTO, INC. - EXPECT 3 MG AND PLACEBO ARMS IN PATIENTS
WHO ARE
NOT ON CONCOMITANT NINTEDANIB OR PIRFENIDONE WILL CONTINUE
ENROLLING PATIENTS
    * GALECTO, INC. - DSMB INFORMED CO BASED ON UNBLINDED SAFETY
&
EFFICACY DATA, THERE WAS AN IMBALANCE IN SERIOUS ADVERSE
EXPERIENCES ACROSS STUDY GROUPS
    * GALECTO, INC. - DSMB INFORMED CO, BASED ON UNBLINDED
SAFETY AND
EFFICACY DATA, THAT THERE WAS NO IMBALANCE BETWEEN GROUPS IN
MORTALITY
    * GALECTO, INC. - DO NOT EXPECT RECOMMENDED CHANGES, WHICH
RELATE
SOLELY TO INHALED GB0139 IN IPF, TO IMPACT ANY OTHER PLANNED
TRIALS
    * GALECTO, INC. - CONTINUE TO LOOK FORWARD TO INITIATING 3
ADDITIONAL PHASE 2 TRIALS THIS YEAR WITH OTHER CLINICAL STAGE
ASSETS GB2064 AND GB1211
    * GALECTO, INC. - ANTICIPATE COMPLETING ENROLLMENT IN
GALACTIC-1
TRIAL THIS YEAR WITH INITIAL DATA READOUT IN 2022

Source text for Eikon:  ID:nGNX9cmrsv 
Further company coverage:  GLTO.O 

 ((Reuters.Briefs@thomsonreuters.com;))